Cardiogen

Cardiogen is a synthetic tetrapeptide (Ala-Glu-Asp-Arg) from the Khavinson bioregulator family, researched for cardiac-tissue-targeted bioregulation, myocardial function, and cardiovascular gene expression. It is one of the synthesized Khavinson compounds with a defined four-amino-acid sequence. Cardiogen is not approved by the FDA, EMA, or any major Western regulator and is sold as a research-use-only compound by third-party laboratories.

What is Cardiogen and how does the cardiac-targeted bioregulatory mechanism work?

Cardiogen is a synthetic Ala-Glu-Asp-Arg tetrapeptide proposed to enter cardiomyocyte nuclei and modulate gene expression in pathways related to myocardial function, ischemic adaptation, and cardiac tissue maintenance. Within the Khavinson framework, Cardiogen is the cardiac-targeted complement to organ-specific bioregulators like Pinealon (pineal/brain) and Cartalax (cartilage). A cardiac (myocardial) target is Cardiogen's designation within the Khavinson framework; independent, Cardiogen-specific preclinical data is not retrievable in the indexed literature, so the proposed cardiac gene-expression mechanism is best read as a family-level hypothesis rather than demonstrated for this peptide. For the framework itself, see the science of Khavinson bioregulators.

Evidence level: Preclinical/mechanistic by analogy to the Khavinson short-peptide class; no Cardiogen-specific study retrievable; independent replication absent

What does the research show for Cardiogen?

Dedicated Cardiogen studies — cardioprotection, rodent cardiac models, or human use — are not published in the searchable record as of August 2026; the compound's positioning rests on the Khavinson group's organ-peptide framework, not on citable Cardiogen efficacy data. No human trial has been conducted. Human clinical research at FDA-grade Phase 2/3 standards has not been conducted.

Evidence level: preclinical (rodent); Khavinson-group research; FDA-grade Phase 2/3 not conducted

How does Cardiogen compare to other Khavinson peptide bioregulators?

Cardiogen is the cardiac-targeted tetrapeptide within the Khavinson cluster, distinguished from the tripeptides by an additional terminal amino acid that the Khavinson framework proposes shifts tissue specificity to cardiac tissue. Sequence convention follows the standard pattern.

What are the documented side effects of Cardiogen?

Side effects in available preclinical data and community-reported research use are mild — injection-site reactions are the most common report. Long-term safety in humans at sustained research-use dosing is not characterized at Western clinical standards.

Evidence level: preclinical safety; human long-term unestablished

What is the regulatory status of Cardiogen?

Cardiogen is not approved by the FDA, EMA, or any major Western regulator as of August 2026. Cardiogen is not on the FDA's active Section 503A/503B Category-2 bulk-substances list and was not among the peptides addressed in the FDA's April 2026 Category-2 actions or the July 2026 Pharmacy Compounding Advisory Committee meeting — no U.S. compounding pathway applies to it. Regulatory context in FDA peptide regulation 2025–2026 timeline.

Source: FDA 503A bulk drug substances (Category 1/2) page

Why does Cardiogen vendor verification matter?

Cardiogen (Ala-Glu-Asp-Arg) shares three of four amino acids with Cartalax (Ala-Glu-Asp) and Epithalon (Ala-Glu-Asp-Gly), making mass spectrometry identity confirmation essential to verify the correct sequence. Independent HPLC purity testing is the standard quality signal. Guidance in how-to-test-peptides hub.

How does Peptigrity verify Cardiogen vendors?

Peptigrity collects independent third-party Certificates of Analysis for Cardiogen from shops' official channels and verifies each for authenticity before publishing. Because shops choose which COAs to publish, results reflect the batches shops have made public rather than every production batch — a selection bias we state openly. A community-funded Testing Grant to purchase and test vials anonymously is in development. Tests in the database come from independent labs such as Janoshik Analytical, Freedom Diagnostics, and Chromate. Methodology in how we calculate trust scores.

Frequently asked questions

What does Cardiogen do?

Cardiogen is proposed to act on cardiac tissue through epigenetic gene-expression modulation, with preclinical research focused on cardioprotection in ischemia models and cardiac gene expression markers. Human Phase 2/3 efficacy is not established at Western clinical standards.

Is Cardiogen legal to purchase?

Cardiogen is legal to purchase as a research chemical for laboratory use in most jurisdictions, but it is not approved for human consumption in the US, EU, or most Western markets. Country breakdown in peptide legal status guide.

Will Cardiogen be FDA-approved?

No active FDA approval pathway exists for Cardiogen as of August 2026.

How can I verify a Cardiogen vendor is selling real product?

Independent third-party HPLC certificate of analysis from a lab the vendor does not own or pay, with mass spectrometry identity confirmation. Mass spec is essential because Cardiogen shares amino acid composition with related Khavinson peptides. COA interpretation in red flags in peptide certificates of analysis.

Does Peptigrity recommend a Cardiogen dose?

No. Cardiogen is not approved for human consumption in Western jurisdictions and Peptigrity is an independent review platform, not a medical authority. Anyone considering use should consult a licensed physician.

Is Cardiogen mechanistically distinct from Western cardiac peptides?

Yes. Cardiogen operates through the proposed Khavinson epigenetic-modulation framework; Western cardiac research peptides like hexarelin work through defined receptor pathways (CD36 in hexarelin's case). They are not mechanistically comparable.

This section is for educational and informational purposes only and does not constitute medical advice. Cardiogen is not approved by the FDA or any major Western regulator for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.